This month the FDA has approved Journavx, a medication that mimics proteins that can help block pain signals from reaching ...

It's the first new type of painkiller in 20 years. And it's just a few weeks away from being here in local pharmacies.

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain. On January 31, the FDA approved Journavx as ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...